However, there is a lack of similar trials for older antihyperglycemic drugs (eg, biguanides, sulfonylurea, insulin) since they were already part of standard therapy for T2DM when the FDA mandate was introduced in 2008. This evidence concerns the gene INS and type 2 diabetes mellitus.